NEW YORK (GenomeWeb) – Quest Diagnostics and Myriad Genetics have settled their patent dispute related to BRCA testing.

Myriad along with its co-patent holders and Quest have agreed to "dismiss their lawsuits, claims, counterclaims, and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation," Quest said in a statement today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.